Design Therapeutics (DSGN) shares were up 3% in recent Wednesday trading after Leerink upgraded its rating on the biopharmaceutical firm's stock to outperform from market perform and adjusted its price target to $14 from $7.
Trading volume stood at about 384,000 shares against a daily average of over 280,000.
Price: 9.21, Change: +0.27, Percent Change: +3.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.